COLLABORATION AND LICENSING AGREEMENTS - Schedule of Recognized Revenue (Details) - USD ($) $ in Thousands	3 Months Ended			6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Mar. 31, 2025	Jun. 30, 2026	Jun. 30, 2025
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue	$ 120,877	$ 97,662		$ 215,350	$ 171,776
Licensing revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue	96	20		147	5,040
Licensing revenue \| Fosun Pharma \| Fosun Pharma
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue	95	0	$ 5,000	115	5,000
Licensing revenue \| Knight \| Knight
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue	1	20		32	40
Product supply revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue	1,976	6,185		2,330	6,439
Product supply revenue \| Fosun Pharma \| Fosun Pharma
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue	1,976	0		2,328	0
Product supply revenue \| Kyowa Kirin \| Kyowa Kirin
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue	0	6,185		2	6,185
Product supply revenue \| Knight \| Knight
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue	0	0		0	254
Non-cash royalty revenue related to the sale of future royalties
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue	676	1,380		1,371	2,406
Non-cash royalty revenue related to the sale of future royalties \| Kyowa Kirin \| Kyowa Kirin
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue	$ 676	$ 1,380		$ 1,371	$ 2,406